Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years -94% of patients remained free from the burden of continuous prophylaxis treatment through five years following a single infusion of HEMGENIX, demonstrating sustained therapeutic benefit- At year five, mean factor IX activity levels remained strong at 36.1% and HEMGENIX continued to demonstrate a favorable safety profile, reinforcing its durable...

#QURE #CSLLY Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years

www.stocktitan.net/news/QURE/data-published...

NEWS: ( OTC: #CSLLY ) Expected US Company Earnings on Tuesday, August 19th, 2025

England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy CSL Vifor announced that FILSPARI® (sparsentan) has received recommendation from England's National Institute for Health and Care Excellence (NICE) for treating IgA nephropathy. The treatment is approved for adults with urine protein excretion ≥1.0 g/day or urine protein-to-creatinine ratio ≥0.75 g/g. This marks the first non-immunosuppressive dual-action therapy recommended for this condition, which affects over 22,000 adults in England. The recommendation follows MHRA authorization in April 2025, with commercial availability expected from July 2025. IgA nephropathy, the most common primary glomerular disease worldwide, leads to kidney failure in 30-40% of patients within 10 years of diagnosis if not properly controlled. The NICE decision requires NHS England to fund the treatment within 90 days of final publication, expected on June 27, 2025.

#CSLLY #TVTX England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy

www.stocktitan.net/news/CSLLY/england-s-nic...

CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy GALLEN, Switzerland and SAN DIEGO, April 29, 2025/ PRNewswire/-- CSL Vifor and Travere Therapeutics, Inc., are pleased to announce that the European Commission has approved the conversion of the conditional marketing approval into a standard marketing authorization for FILSPARI for the treatment of adults with primary IgA nephropathy with a urine protein...

#CSLLY #TVTX CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy

www.stocktitan.net/news/CSLLY/csl-vifor-and...

Revolutionary COVID Vaccine Breakthrough: New Technology Shows Year-Long Immunity in EU Approval CSL's KOSTAIVE, outperforming traditional mRNA vaccines with 12-month antibody persistence, receives EU-wide authorization for adults 18+

#CSLLY #ARCT European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine

www.stocktitan.net/news/CSLLY/european-comm...

Revolutionary COVID Vaccine Breakthrough: EU Approves KOSTAIVE with Year-Long Immunity Power European Commission authorizes groundbreaking sa-mRNA COVID vaccine showing superior antibody response and year-long protection versus traditional mRNA vaccines.

#ARCT #CSLLY European Commission Approves CSL and Arcturus Therapeutics’ KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine

www.stocktitan.net/news/ARCT/european-commi...

BREAKING NEWS: ( OTC: #CSLLY ) CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI (sparsentan) for the treatment of IgA Nephropathy

#StockMarket #News